Amicus Therapeutics Inc. (FOLD)
Symbol Info
Listed Symbol FOLD
Name Amicus Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $91,245,000
Latest Fiscal EPS $-1.86
Price Info
21 Day Moving Average $9.7343
21 Day EMA $9.886050
50 Day Moving Average $10.9224
50 Day EMA $10.575880
200 Day EMA $11.835590
200 Day Moving Average 11.827200
52 Week High $14.62
52 Week Low $8.27
52 Week Change $-25.118900
Alpha 0.010802
Beta 1.5696
Standard Deviation 0.171841
R2 0.098913
Periods 60
Share Information
10 Day Average Volume 4,009,379
20 Day Average Volume 3,943,448
30 Day Average Volume 3,891,746
50 Day Average Volume 3,667,162
Outstanding Shares 254,626,063
Float Shares 251,670,257
Percent Float 98.84%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 442
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 31,356,533
Institute Holdings Percent -
Institute Sold Previous 3 Months 21,984,161
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 2,955,806
Price Change
7 Day Price Change $-0.3500004
7 Day Percent Change -3.57%
21 Day Price Change $-0.4400005
21 Day Percent Change -4.45%
30 Day Price Change $-0.8200007
30 Day Percent Change -7.98%
Month To Date Price Change $-0.44
Month To Date Percent -4.45%
90 Day Price Change $-3.01
90 Day Percent Change -24.16%
Quarter To Date $-3.03
Quarter To Date Percent -24.28%
180 Day Price Change $-3.92
180 Day Percent Change -29.32%
200 Day Price Change $-4.45
200 Day Percent Change -32.01%
Year To Date $-0.13
Year To Date Percent -1.36%
Profile
Description Amicus Therapeutics Inc is a global biotechnology company that aims to treat rare and orphan diseases. The company's strategy focuses on global capacity with an international infrastructure, late-stage product acquisition, and biologics manufacturing. Amicus leverages its pharmacological technology to develop treatments for human genetic diseases by targeting mutated proteins. The company utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products.
Details
Issue Type CS
Market Cap $2,406,216,295
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 254,626,063
CEO John F. Crowley
Employees 508
Last Audit UQ
Classification
CIK 0001178879
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 1 Cedar Brook Drive
Cranbury, NJ 8512
Website http://www.amicusrx.com
Facisimile +1 609 662-2001
Telephone +1 609 662-2000
Email info@amicusrx.co.uk
Key Ratios
Profitability
EBIT Margin -316.4
EBITDA Margin -313.1
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin 86.20
Profit Margin TOT -
Income Statements
Revenue $131,416,000
Revenue Per Share $0.5161
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $2,046,570,162
Price To Sales 18.309920
Price To Free Cash -7.4
PE High Last 5 Years -
Price To Book 4.2
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 6.6
Financial Strength
Total Debt To Equity 0.3
Int Coverage -17
Current Ratio 7.1
Leverage Ratio 1.8
Quick Ratio 6.7
Long Term Debt To Capital 0.24
Assets
Receivables Turnover 3.8
Invoice Turnover 2.00
Assets Turnover 0.10
Management Effectiveness
Return Assets -50.7
Return On Equity -76.09
Return On Capital -56.33
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
FOLD
Amicus The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.